INSTITUT PASTEUR DE LILLE Patent applications |
Patent application number | Title | Published |
20150224129 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA WITH INVARIANT NKT CELL AGONISTS - The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with iNKT cell agonists. | 08-13-2015 |
20150045506 | NATIVE LIGATION PROCESS - A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described. | 02-12-2015 |
20140309238 | FLUORALKYLCARBONYL-OXADIAZOLES - The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals: (II); (III); (IV), (V), (VI) (VII) and n=1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis. | 10-16-2014 |
20140271563 | EFFECT OF AN ATTENUATED BORDETELLA STRAIN AGAINST ALLERGIC DISEASE - Described herein are compositions, vaccines, and methods that include use of a mutated | 09-18-2014 |
20140206601 | Methods and Pharmaceutical Compositions for the Treatment of Respiratory Tract Infections - The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection. | 07-24-2014 |
20140088184 | Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus - The present invention relates to a flavonoid compound having the formula I, where R3, R5 and/or R7 is a group having the formula II, or R1 and R2 are both OH groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis C virus (HCV) infection. The invention also relates to an ex vivo method for reducing the infectivity of HCV or for inactivating HCV, including a step of contacting said hepatitis C virus with a compound having the formula (I). | 03-27-2014 |
20130217717 | COMPOUND USEFUL FOR THE TREATMENT OF NONSENSE-MUTATION-MEDIATED DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND - The present invention relates to the compound of formula (I) | 08-22-2013 |
20130183336 | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology - The present invention relates to a life attenuated | 07-18-2013 |
20120238461 | METHOD FOR DETERMINING THE RISK OF OCCURRENCE OF ALZHEIMER'S DISEASE - The present invention relates to an in vitro method for determining that an individual is at risk of developing Alzheimer's disease, which comprises: —determining whether the individual harbours at least one variant allele of a susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR 1); —deducing that if the individual harbours at least one variant allele of the APOJ and/or CR1 gene, then the individual is at risk of developing Alzheimer's disease. | 09-20-2012 |
20120220721 | Method for Native Ligation of Polypeptides - The invention mainly relates to a method for manufacturing a polypeptide of formula: | 08-30-2012 |
20120177688 | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology - The present invention relates to a life attenuated | 07-12-2012 |
20120121647 | INFLUENZA VACCINE, COMPOSITION, AND METHODS OF USE - The invention relates to compositions and vaccines that include a mutated | 05-17-2012 |
20120088259 | Post-Translation Modified Cardiac Troponin T As A Biomarker Of A Risk For Heart Failure - The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker. | 04-12-2012 |
20120015387 | MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT - An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa. | 01-19-2012 |
20110301092 | THE USE OF A NON-GLYCANATED POLYPEPTIDE FOR TREATING A CANCER - The use of a non-glycanated form of a polypeptide including an amino acid sequence having at least 90% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 and SEQ ID No 2 for manufacturing a medicament for preventing or treating a cancer. | 12-08-2011 |
20110136823 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF - The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy. | 06-09-2011 |
20110123981 | FTO GENE POLYMORPHISMS ASSOCIATED TO OBESITY AND/OR TYPE II DIABETES - The present invention provides means and methods for risk assessment and/or diagnosis and/or prognosis of obesity and/or type II diabetes in humans, based on the detection of nucleic acid biomarkers belonging to, or associated with, a set of SNPs in the fatso (FTO) gene. The present invention also provides means and methods for identifying a SNP haplotype associated with obesity and/or type II diabetes susceptibility in humans, for selecting pharmaceutical agents useful in prevention and/or treatment of obesity and/or type II diabetes in humans, for haplotyping the fatso (FTO) gene in humans. | 05-26-2011 |